Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 1, 2008, Pages

  Banfor, Patricia N ^a   Preusser, Lee C ^a   Campbell, Thomas J ^a   Marsh, Kennan C ^a   Polakowski, James S ^a   Reinhart, Glenn A ^a   Cox, Bryan F ^a   Fryer, Ryan M ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL; DOBUTAMINE; DRUG METABOLITE; LEVOSIMENDAN; MILRINONE; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; OR 1855; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG EFFECT; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HEMODYNAMICS; MALE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PULSE PRESSURE; SYSTEMIC CIRCULATION; SYSTEMIC VASCULAR RESISTANCE; VASCULAR RESISTANCE; VASODILATATION;

ACETAMIDES; ANIMALS; BLOOD PRESSURE; CALCIUM; CARDIAC OUTPUT; CARDIOTONIC AGENTS; CARDIOVASCULAR SYSTEM; DOBUTAMINE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; HYDRAZONES; MALE; MILRINONE; MYOCARDIAL CONTRACTION; OXYGEN CONSUMPTION; POTASSIUM; POTASSIUM CHANNELS; PULMONARY CIRCULATION; PYRIDAZINES; TIME FACTORS; VASCULAR RESISTANCE; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 38149072221     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01181.2007     Document Type: Article

References (50)

1. Antila S, Pesonen U, Lehtonen L, Tapanainen P, Nikkanen H, Vaahtera K, Scheinin H. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci 23: 213-222, 2004.
2. Antila S, Sundberg S, Lehtonen LA. Clinical pharmacology of levosimendan. Clin Pharmacokinet 46: 535-552, 2007.
3. Blacher J, Staessen JA, Girerd X, Gasowski J, Thijs L, Liu L, Wang JG, Fagard RH, Safar ME. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 160: 1085-1089, 2000.
4. 2+ sensitizer levosimendan in human myocardium. Am J Physiol Heart Circ Physiol 282: H131-H137, 2002.
5. Chatterjee K. 'Unloading' therapy for heart failure. West J Med 147: 324-325, 1987.
6. De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. Eur Heart J 27: 1908-1920, 2006.
7. De Witt BJ, Ibrahim IN, Bayer E, Fields AM, Richards TA, Banister RE, Kaye AD. An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg 94: 1427-1433, 2002.
8. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 77: 107-113, 1995.
9. Endoh M, Hori M. Acute heart failure: inotropic agents and their clinical uses. Expert Opin Pharmacother 7: 2179-2202, 2006.
10. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360: 196-202, 2002.
11. Fryer RM, Preusser LC, Calzadilla SV, Hu Y, Xu H, Marsh KC, Cox BF, Lin CT, Gopalakrishnan M, Reinhart GA. (-)-(9S)-9-(3-Bromo-4-fluorophenyl)- 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine. J Cardiovasc Pharmacol 44: 137-147, 2004.
12. Fryer RM, Rakestraw PA, Preusser LC, Brune ME, Carroll WA, Buckner SA, Shieh CC, King LL, Marsh KC, Gopalakrishnan M, Cox BF, Reinhart GA. Pharmacological characterization of the novel dihydropyridine potassium channel opener, (9R)-9-(3-iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e] pyridine-1,8(4H,7H)-dione (A-325100), and the regulation of cardiovascular function in conscious and anesthetized beagle dogs. J Cardiovasc Pharmacol 46: 232-240, 2005.
13. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, Bang L, Olesen SP, Aldershvile J. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 31: 741-749, 1998.
14. Haikala H, Kaheinen P, Levijoki J, Linden IB. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 34: 536-546, 1997.
15. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 27: 1859-1866, 1995.
16. Haikala H, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol 27: 2155-2165, 1995.
17. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 25: 794-801, 1995.
18. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 98: 2141-2147, 1998.
19. + channels in dobutamine-induced relaxation in rat mesenteric artery. Clin Exp Pharmacol Physiol 25: 405-411, 1998.
20. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol 43: 555-561, 2004.
21. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 37: 367-374, 2001.
22. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-h continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 40: 465-471, 2002.
23. Kivikko M, Lehtonen L. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des 11: 435-455, 2005.
24. Kristof E, Szigeti G, Papp Z, Bodi A, Facsko A, Kovacs L, Papp JG, Kranias EG, Edes I. Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts. Effects on cyclic AMP levels, protein phosphorylation, myoplasmic calcium concentration, and left ventricular function. Ann NY Acad Sci 853: 316-319, 1998.
25. i in guinea-pig isolated ventricular myocytes. Eur J Pharmacol 339: 97-100, 1997.
26. Lehmann A, Boldt J, Kirchner J. The role of Ca++-sensitizers for the treatment of heart failure. Curr Opin Crit Care 9: 337-344, 2003.
27. Lilleberg J, Sundberg S, Hayha M, Akkila J, Nieminen MS. Haemodynamic dose-efficacy of levosimendan in healthy volunteers. Eur J Clin Pharmacol 47: 267-274, 1994.
28. Lilleberg J, Sundberg S, Nieminen MS. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 26, Suppl 1: S63-S69, 1995.
29. Masoni A, Alboni P, Malacarne C, Codeca L. Effects of dobutamine on electrophysiological properties of the specialized conduction system in man. J Electrocardiol 12: 361-370, 1979.
30. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M. Levosimendan vs. dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297: 1883-1891, 2007.
31. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23: 1422-1432, 2002.
32. Ng TM, Akhter MW. Levosimendan: dual mechanisms for acute heart failure. . . and beyond? Minerva Cardioangiol 53: 565-584, 2005.
33. Pagel PS, Hettrick DA, Warltier DC. Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency. Basic Res Cardiol 91: 296-307, 1996.
34. Pataricza J, Hohn J, Petri A, Balogh A, Papp JG. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 52: 213-217, 2000.
35. Pataricza J, Krassoi I, Hohn J, Kun A, Papp JG. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 17: 115-121, 2003.
36. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 269: 28584-28590, 1994.
37. Rump AF, Acar D, Rosen R, Klaus W. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol 74: 244-248, 1994.
38. 2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 30: 1115-1128, 1998.
39. Scalia GM, Greenberg NL, McCarthy PM, Thomas JD, Vandervoort PM. Noninvasive assessment of the ventricular relaxation time constant (tau) in humans by Doppler echocardiography. Circulation 95: 151-155, 1997.
40. Shin DD, Brandimarte F, De Luca L, Sabbah HN, Fonarow GC, Filippatos G, Komajda M, Gheorghiade M. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 99: 4A-23A, 2007.
41. Sorsa T, Heikkinen S, Abbott MB, Abusamhadneh E, Laakso T, Tilgmann C, Serimaa R, Annila A, Rosevear PR, Drakenberg T, Pollesello P, Kilpelainen I. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem 276: 9337-9343, 2001.
42. Sorsa T, Pollesello P, Permi P, Drakenberg T, Kilpelainen I. Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides. J Mol Cell Cardiol 35: 1055-1061, 2003.
43. Szilagyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, Papp Z. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 486: 67-74, 2004.
44. 2+ transients under acidotic condition in aequorin-loaded canine ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 366: 440-448, 2002.
45. Takahashi R, Talukder MA, Endoh M. Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium. J Cardiovasc Pharmacol 36: 118-125, 2000.
46. Takahashi R, Talukder MA, Endoh M. Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur J Pharmacol 400: 103-112, 2000.
47. Teerlink JR. The development of new medical treatments for acute decompensated heart failure. Heart Fail Monit 2: 129-137, 2002.
48. Virag L, Hala O, Marton A, Varro A, Papp JG. Cardiac electrophysiological effects of levosimendan, a new calcium sensitizer. Gen Pharmacol 27: 551-556, 1996.
49. + channel in rat arterial myocytes. Eur J Pharmacol 333: 249-259, 1997.
50. + channel in rat ventricular cells. J Pharmacol Exp Ther 283: 375-383, 1997.